Probucol

Current Atherosclerosis Reports

Volumn 2, Issue 1, 2000, Pages 47-57

  Pfuetze, Karl D ^a   Dujovne, Carlos A ^a  

^a Kansas Foundation for Clinical Pharmacology   (United States)

Author keywords

Arterioscler Thromb Vasc Biol; Cholesterol; Cholesterol Ester Transfer Protein; Probucol; Reverse Cholesterol Transport

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; HYPOCHOLESTEROLEMIC AGENT; PROBUCOL;

ANIMAL; ARTERIOSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT; RAT; REVIEW; VASCULAR RESISTANCE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MYOCARDIAL INFARCTION; PROBUCOL; RABBITS; RATS; VASCULAR RESISTANCE;

EID: 0033751091     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-000-0094-0     Document Type: Article

References (39)

1. Davignon J: Pleiotropic effects of drugs affecting lipid metabolism. Newsletter of the International Atherosclerosis Society, 1999:2.
2. Inouye M, Hashimoto H, Abo K, et al.: The effect of probucol on oxidized cholesterol disposition in hyperlipidaemic patients. J Intern Med Res 1998, 26:233–238.
3. Plump A, Masucci-Magoulas L, Bruce C, et al.: Increased atherosclerosis in apoe and ldl receptor gene knock-out mice as a result of human cholesterol ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999, 19:1105–1110.
4. Kita T, Nagano Y, Yokode M, et al.: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci (USA) 1987, 84:5928–5931. DOI: 10.1073/pnas.84.16.5928
5. Carew T, Schwenke D, Steinberg D, et al.: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophagerich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci (USA) 1987, 84:7725–7729. DOI: 10.1073/pnas.84.21.7725
6. Kita T, Nagano Y, Yokode M, et al.: Prevention of atherosclerotic progression in Watanabe rabbits on probucol. Am J Cardiol 1988, 62:13B.
7. Dujovne C, Harris W, Colle Gerrond L, et al.: Comparison of effects of probucol versus vitamin on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia. Am J Med 1994, 74:38.
8. Nunes G, Sgoutas D, Redden R, et al.: Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol 1995, 15:156–165.
9. Tamminen M, Mottino G, Qiao J, et al.: Ultrastructure of early lipid accumulation in apoE-deficient mice. Arterioscler Throm Vasc Biol 1999, 19:847–853.
10. Nakashima Y, Plump A, Raines E, et al.: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133–140.
11. Aburatani H, Matsumoto A, Kodama T, et al.: Increased levels of messenger ribonucleic acid for apolipoprotein E in the spleen of Probucol-treated rabbits. Amer J Cardiol 1988, 61:60B.
12. Singal P, Iliskovic N, Li T, et al.: Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997, 11:931–936.
13. Li L, Chen J, Liao D, et al.: Probucol inhibits oxidized-low density lipoprotein-induced adhesion of monocytes to endothelial cells by reducing P-selectin synthesis in vitro. Indothelium 1998, 6:18.
14. Hoshida S, Yamashita N, Igarashi J, et al.: Long-term probucol treatment reverses the severity of myocardial injury in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 1997, 17:2801–2807.
15. Anderson TJ, Meredith IT, Yeung AC, et. al.: The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488–493. DOI: 10.1056/NEJM199502233320802
16. Inoue N, Ohara Y, Fukai T, et al.: Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits. Am J Med Sci 1998, 315:242–247. DOI: 10.1097/00000441-199804000-00005
17. Boger P, Bode-Boger S, Szuba A, et al.: Asymmetric dimethyl-arginine (adma): a novel risk factor for endothelial dysfunction, its role in hypercholesterolemia. Circulation 1998, 98:1842–1847.
18. Bonsack M, Felemovicius I, Baptista M, et al.: Radioprotection of the intestinal mucosa of rats by probucol. Radation Res 1999, 151:69–73. DOI: 10.2307/3579749
19. Ito M, Suzuki Y, Ishihara M, et al.: Anti-ulcer efforts of antioxidants: effect of probucol. Eur J Pharmacol 1998, 354:189–196. DOI: 10.1016/S0014-2999(98)00448-8
20. Yasunari K, Kohno M, Kano H, et al.: Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Circulation 1999, 99:1370–1378.
21. Eddy AA: Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Intern 1998, 53:1182–1189. DOI: 10.1046/j.1523-1755.1998.00889.x
22. Li S, Forster L, Anggard E, et al.: RT-PCR study on the effects of minimally modified low-density lipoproteins and probucol treatment on gene expressions of interleukin-1 and platelet-derived growth factor b-chain in human peripheral blood mononuclear cells. Biol Signals 1966, 5:263–274.
23. Li S, Forster L, Anggard E, et al.: The effects of lps and probucol on interleukin i (il-1) and platelet-derived growth factor (pdgf) gene expression in the human monocytic cell line u-937. Biochemica et Biophysica Acta 1994, 1225:271–274. DOI: 10.1016/0005-2736(94)90309-3
24. Akeson A, Woods C, Mosher L, et al.: Inhibition of il-ib expression in thp-1 cells by probucol and tocopherol. Atherosclerosis 1991, 86: 261–270. DOI: 10.1016/0021-9150(91)90222-O
25. Tanaka K, Hayashi K, Shingu T, et al.: Probucol inhibits neointiman formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells. Cardiovasc Drugs Ther 1998, 12:19–28. DOI: 10.1023/A:1007777128574
26. Miyauchi K, Aikawa M, Tani T, et al.: Effect of Probucol on smooth muscle cell proliferation and dedifferentiation after vascular injury in rabbits: possible role of pdgf. Cardiovasc Drugs Ther 1998, 12:251–260. DOI: 10.1023/A:1007761631674
27. Itoh H, Komori K, Okazaki J, et al.: The effect of Probucol on intimal thickening of autologous vein grafts in hyperlipidemic rabbit. Cardiovasc Surg 1997; 5:497. DOI: 10.1016/S0967-2109(97)00059-8
28. Grafe M, Auch-Schwelk W, Hertel H, et al.: Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL. Atherosclerosis 1998, 137:87–95. DOI: 10.1016/S0021-9150(97)00258-X
29. Baldasarre D, Franceschini G, Peruzzotti G, et al.: Clinical evaluation of probucol in hypercholesterolemia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. J Cardiovasc Pharmacol 1997, 30:784–789. DOI: 10.1097/00005344-199712000-00013
30. Tardil J-C, Cote G, Lesperance J, et al.: Probucol and multiviamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997, 337:365–372. DOI: 10.1056/NEJM199708073370601
31. Yokoi H, Daida H, Kuwabara Y, et al.: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial. J Amer Coll Cardiol 1997, 30:855–862. DOI: 10.1016/S0735-1097(97)00270-2
32. Sekiya M, Funada J, Watanabe K, et al.: Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Amer J Cardiol 1998, 82:144–147. DOI: 10.1016/S0002-9149(98)00323-3
33. Cote G, Tardif J-C, Lesperance J, et al.: Effects of Probucol on vascular remodeling after coronary angioplasty. Circulation 1999, 99:30–35.
34. Lussier-Cacan S, Dubreuil-Quidoz S, Roederer G, et al.: Influence of probucol on enhanced LDL oxidation after fish oil treatment of hypertriglyceridemic patients. Arterioscler Thromb 1993, 13:1790–1797.
35. Yamamoto A, Hara H, Takaichi S, et al.: Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Amer J Cardiol 1988, 62:31B.
36. Oshima R, Ikeda T, Watanabe K, et al.: Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 1998, 137:13–22. DOI: 10.1016/S0021-9150(97)00243-8
37. Goldberg R, Mendez A: Probucol enhances cholesterol efflux from cultured human skin fibroblasts. Amer J Cardiol 1988, 62:57B.
38. Jiafu O, Keijiro S, Shiro J, et al.: Mechanism of action of probucol on cholesterolester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene. Biochimica et Biophysica Acta 1998, 1393:153–160.
39. Barnhart J, Li D, Cheng W, et al.: Probucol enhances cholesterol transport in cultured rat hepatocytes. Amer J Cardiol 1988, 62:52B.